Pluvicto

Crescent Theranostics

What Is Pluvicto?

Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) is a breakthrough radioligand therapy approved by the FDA to treat metastatic castration-resistant prostate cancer (mCRPC) in patients who have already received other treatments such as androgen receptor pathway inhibitors and chemotherapy.

Pluvicto works by delivering targeted radiation directly to prostate cancer cells that express PSMA (prostate-specific membrane antigen), a protein found on most advanced prostate tumors. This precision-targeted approach helps slow disease progression, reduce symptoms, and improve quality of life—while sparing surrounding healthy tissue.